Mechanism of Action
PROKR1/2-Mediated Angiogenesis
PROK1 binds PROKR1 and PROKR2 with similar affinity, activating Gq and Gi signaling pathways. In endothelial cells of steroidogenic organs, PROKR activation promotes proliferation, survival, fenestration (formation of endothelial pores important for hormone secretion), and migration. The tissue-specific pattern of PROKR expression restricts angiogenic effects to these organs. PROK1 is uniquely induced by hCG in the corpus luteum, driving luteal angiogenesis essential for early pregnancy.
Nociception and Circadian Rhythm
Beyond angiogenesis, PROK1 and PROKR2 are expressed in dorsal root ganglia where PROKR activation causes pain hypersensitization (hyperalgesia and allodynia) through voltage-gated calcium channel modulation. PROK2 (prokineticin-2) in the suprachiasmatic nucleus regulates circadian rhythm output. The dual role in tissue angiogenesis and sensory pain processing makes the prokineticin system a target for both fertility disorders and pain conditions.
Research Summary
Endometriosis and Reproductive Biology
PreclinicalPROK1 expression is elevated in endometriotic lesions, and PROKR1 is overexpressed in endometrioma epithelium. PROKR antagonists reduce endometriotic lesion growth and vascularization in mouse models. PROK1 also mediates early pregnancy vascular development in the first trimester, where PROKR1/2 mutations are associated with recurrent miscarriage. These findings position the prokineticin system as a therapeutic target for endometriosis and implantation disorders.
Kallmann Syndrome
Genetic Disease AssociationLoss-of-function mutations in PROKR2 are a known cause of Kallmann syndrome (hypogonadotropic hypogonadism with anosmia). PROK2 and PROKR2 are required for olfactory bulb morphogenesis and GnRH neuron migration. While PROK1 mutations are less commonly linked to Kallmann syndrome, the pathway is essential for reproductive neuroendocrine development. Understanding prokineticin biology has clarified several gene variants in patients with idiopathic infertility.
Calculate your Prokineticin-1 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Angiogenesis (in vitro) | 1-10 nM (recombinant PROK1) | Continuous exposure | Direct application |
| Endometriosis (mouse) | PROKR antagonist 1-10 mg/kg | Daily | IP / SC (research) |
No human protocols for PROK1 itself. PROKR antagonists are the therapeutic targets under investigation.
Interactions
Safety Profile
As an endogenous protein, PROK1 at physiological levels is well tolerated. The pain-sensitizing effects through PROKR1 in sensory neurons are a potential concern for exogenous PROK1 administration. PROKR antagonists targeting endometriosis angiogenesis must be used cautiously in women planning pregnancy given essential roles in early implantation. No human clinical data for recombinant PROK1 therapeutics.
References
- [1]LeCouter J, et al. (2001). Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature, 412(6850), 877-884.
- [2]Battersby S, et al. (2004). Expression of the PROKINETICIN protein EG-VEGF in ovarian endometriosis. J Clin Endocrinol Metab, 89(6), 2929-2935.